Double Bond Pharmaceutical International AB

http://www.doublebp.com/

Last activity: 21.07.2026

Active

Categories: BiotechDrugDeliveryHealthcareOncologyPharmaceutical

Double Bond Pharmaceutical (DBP) was established in 2014 in Uppsala, Sweden, and today is one of the fastest growing pharmaceutical companies in Sweden. DBP has developed a technology allowing to control where the medicines go once injected into the body. Thanks to this technology called BeloGal(R) it is now possible to dramatically decrease the side effects of the chemotherapeutic anti-cancer treatments and increase the effect and success rate of the therapies. More about DBP here: www.doublebp.com

Twitter Facebook LinkedIn Youtube Email

Likes

Followers

595

Mentions

Overview

Location

Sweden

Employees

1-10

Founded date

2014

Mentions in press and media 24

Reviews 0

FAQ about Double Bond Pharmaceutical International AB

When was Double Bond Pharmaceutical International AB founded?

Double Bond Pharmaceutical International AB was founded in 2014.

What has the press written about Double Bond Pharmaceutical International AB?

Parsers VC has collected 24 articles mentioning Double Bond Pharmaceutical International AB, among them “Double Bond Pharmaceutical to Present Clinical Real-World Evidence Data for SI053 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia” (Jul 21, 2026) and “Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia” (May 25, 2026).

Is Double Bond Pharmaceutical International AB still active?

Yes, Double Bond Pharmaceutical International AB is active; its latest activity on Parsers VC dates from Jul 21, 2026.

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jul 21, 2026	Double Bond Pharmaceutical to Present Clinical Real-World Evidence Data for SI053 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia	Double Bond Pharmaceutical to Present Clinical Real-World Evidence Data for SI053 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia Tue, Jul 21, 2026 14:47 CET Report this content UPPSALA, SWEDEN — July 21, 2026 — ...
May 25, 2026	Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia	Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia Mon, May 25, 2026 14:45 CET Report this content Double Bond Pharmaceutical International AB (publ) (“DBP”) today announces that a...
May 6, 2026	Double Bond Pharmaceutical’s Abstract on Temodex Accepted for Presentation at EANS2026	Double Bond Pharmaceutical’s Abstract on Temodex Accepted for Presentation at EANS2026 Wed, May 06, 2026 13:04 CET Report this content Double Bond Pharmaceutical AB (publ) (“DBP”) announces that a scientific abstract regarding its lead prod...
Apr 28, 2026	Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed	Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed Tue, Apr 28, 2026 18:00 CET Report this content Double Bond Pharmaceutical AB (publ) ("DBP") reports the...
Mar 26, 2026	Double Bond Pharmaceutical Collaborates with Karolinska Institutet in Stockholm for Advanced RWE Analysis of Temodex	Double Bond Pharmaceutical Collaborates with Karolinska Institutet in Stockholm for Advanced RWE Analysis of Temodex Thu, Mar 26, 2026 07:30 CET Report this content Uppsala, Sweden – March 26, 2026 – Double Bond Pharmaceutical AB (publ) (“D...
Feb 19, 2026	Double Bond Pharmaceutical Reports Preliminary Survival Data from Large-Scale Retrospective Study of Temodex	Double Bond Pharmaceutical Reports Preliminary Survival Data from Large-Scale Retrospective Study of Temodex Thu, Feb 19, 2026 18:03 CET Report this content UPPSALA, SWEDEN – February 19, 2026 – Double Bond Pharmaceutical AB (publ) (“DBP”) ...
Feb 12, 2026	Double Bond Pharmaceutical AB Signs Strategic Agreement for Landmark Clinical Study of Temodex® Based on Latest WHO Standards	Double Bond Pharmaceutical AB Signs Strategic Agreement for Landmark Clinical Study of Temodex® Based on Latest WHO Standards Thu, Feb 12, 2026 18:00 CET Report this content UPPSALA, SWEDEN (February 12, 2026) – Double Bond Pharmaceutical A...
Jun 24, 2025	Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053	Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053 Tue, Jun 24, 2025 08:00 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP&q...
Jun 17, 2025	Double Bond Pharmaceutical International AB (publ) Qualifies New Swedish EU-GMP-Approved Supplier for Key Component of SI-053	Double Bond Pharmaceutical International AB (publ) Qualifies New Swedish EU-GMP-Approved Supplier for Key Component of SI-053 Tue, Jun 17, 2025 10:59 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP"...
Mar 10, 2025	Promising Advances in Cancer Treatment: A Look at Recent Developments in Glioblastoma and Prostate Cancer Therapies	In the ever-evolving landscape of cancer treatment, two recent developments stand out: the collaboration between DBP International AB and Vivo Biopharma LLC on SI-053, and the SECuRE trial's promising results for 67Cu-SAR-bisPSMA. Both init...
Mar 10, 2025	DBP International AB and Vivo Biopharma LLC Extend Asset Purchase and Collaboration Agreements for SI-053	DBP International AB and Vivo Biopharma LLC Extend Asset Purchase and Collaboration Agreements for SI-053 Mon, Mar 10, 2025 06:00 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP") and Vivo Biopharm...
Feb 20, 2025	Promising Advances in Obesity and Glioblastoma Treatments: A Dual Spotlight on ASC30 and SI-053	In the ever-evolving landscape of medical research, two companies have recently made headlines with their promising advancements in treatments for obesity and glioblastoma. Ascletis Pharma Inc. and Double Bond Pharmaceutical International A...
Feb 19, 2025	DBP International AB Optimizes Manufacturing Process for SI-053 Ahead of Phase 1 Clinical Trial in Glioblastoma	DBP International AB Optimizes Manufacturing Process for SI-053 Ahead of Phase 1 Clinical Trial in Glioblastoma Wed, Feb 19, 2025 11:38 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP" or "The...
Sep 19, 2024	Telix and Cardinal Health: A New Era in Kidney Cancer Diagnostics	In the ever-evolving landscape of cancer diagnostics, Telix Pharmaceuticals Limited has made a significant move. The Australian biopharmaceutical company has chosen Cardinal Health, Inc. as its U.S. commercial distributor for Zircaix® (TLX2...
Sep 17, 2024	DBP International AB: transition of the SI053 clinical trials protocol to a new Clinical Trial Information System has been completed	DBP International AB: transition of the SI053 clinical trials protocol to a new Clinical Trial Information System has been completed Tue, Sep 17, 2024 07:00 CET Report this content Double Bond Pharmaceutical International AB (publ) ("D...
Jun 4, 2024	DBP International AB and Vivo Biopharma LLC: Revised Asset Purchase and Collaboration Agreements	DBP International AB and Vivo Biopharma LLC: Revised Asset Purchase and Collaboration Agreements Tue, Jun 04, 2024 06:30 CET Report this content Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), tod...
May 29, 2024	DBP International AB: European patent for the technology platform BeloGal® is granted	DBP International AB: European patent for the technology platform BeloGal® is granted Wed, May 29, 2024 07:30 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP" or the "Company", org. no. 5...
Sep 19, 2023	Supplement to Press Release: DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment	Supplement to Press Release: DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment Tue, Sep 19, 2023 22:23 CET Report this content The ...
Sep 17, 2023	DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment	DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment Sun, Sep 17, 2023 11:00 CET Report this content Double Bond Pharmaceutical Intern...
Feb 11, 2022	DBP International AB: Japanese patent for Temodex / SI-053 is granted	DBP International AB: Japanese patent for Temodex / SI-053 is granted Fri, Feb 11, 2022 10:29 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has ...
Feb 7, 2022	DBP International AB: a new patent for SA-033 is granted in Japan	DBP International AB: a new patent for SA-033 is granted in Japan Mon, Feb 07, 2022 08:30 CET Report this content Double Bond Pharmaceutical's forth patent application for organ-specific administration of hydrophilic cancer drug to the live...
Nov 18, 2021	DBP International: 20% of the shares of Bio Vitos is received	Double Bond Pharmaceutical International AB (publ) ("DBP") is today able to confirm that it has received as agreed 10,010,000 (ten million and ten thousand) new ordinary shares of GBX 0.1 par value each of Bio Vitos, representing ...
Oct 25, 2021	DBP International AB: a new patent for SA-033 is granted in China	DBP International AB: a new patent for SA-033 is granted in China Mon, Oct 25, 2021 10:57 CET Double Bond Pharmaceutical's third patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the ba...